Pangaea Oncology (XMAD:PANG) Long-Term Debt: €2.17 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:PANG Pangaea Oncology SA XMAD:PANG
65 GF Score
Price €1.55
GF Value €2.19
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology Long-Term Debt?

Pangaea Oncology XMAD:PANG 65 Long-Term Debt is €2.17 Mil as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 65/100 and a GF Value™ of €2.19 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Pangaea Oncology's Long-Term Debt for the quarter that ended in Dec. 2025 was €2.17 Mil.

Pangaea Oncology's quarterly Long-Term Debt increased from Dec. 2024 (€1.71 Mil) to Jun. 2025 (€1.99 Mil) and increased from Jun. 2025 (€1.99 Mil) to Dec. 2025 (€2.17 Mil).

Pangaea Oncology's annual Long-Term Debt declined from Dec. 2023 (€1.86 Mil) to Dec. 2024 (€1.71 Mil) but then increased from Dec. 2024 (€1.71 Mil) to Dec. 2025 (€2.17 Mil).

Pangaea Oncology  (XMAD:PANG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Pangaea Oncology Long-Term Debt Related Terms

Pangaea Oncology Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Pangaea Oncology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pangaea Oncology Long-Term Debt Chart

Pangaea Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.27 2.29 1.86 1.71 2.17

Pangaea Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 1.54 1.71 1.99 2.17
XMAD:PANG
65GF Score
Pangaea Oncology SA XMAD:PANG
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €2.17 Mil mean?
Pangaea Oncology (XMAD:PANG) has a Long-Term Debt of €2.17 Mil as of Dec. 2025.
Is Pangaea Oncology's Long-Term Debt too high?
Pangaea Oncology's current Long-Term Debt is €2.17 Mil. Overall, Pangaea Oncology has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Long-Term Debt compare to TMO and DHR?
Pangaea Oncology's Long-Term Debt of €2.17 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Pangaea Oncology's current Long-Term Debt is €2.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.19, compared to a current price of €1.55 — trading 29.2% below its estimated fair value. The current Long-Term Debt is €2.17 Mil. Pangaea Oncology's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Long-Term Debt is €2.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.55 is trading 29.2% below its estimated GF Value™ of €2.19. GuruFocus considers Pangaea Oncology to be Modestly Undervalued.

Key valuation signals for XMAD:PANG:

  • Long-Term Debt: €2.17 Mil
  • GF Value™: €2.19 vs. price of €1.55 (29.2% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
65GF Score

Get the complete analysis for XMAD:PANG

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€2.19
GF Value